A Medtronic insider sale disclosed in an SEC Form 4 shows Michael Marinaro sold 10,420 ordinary shares on October 15, 2026, at $96 each, totaling $1,000,320. The executive vice president and president of Medical Surgical and Americas retained 105,916 shares directly. The transaction followed a trading plan adopted seven months earlier.
Key Takeaways
- Marinaro sold just over $1 million in Medtronic shares at $96 apiece.
- The transaction was made under a Rule 10b5-1 plan adopted on March 17, 2026.
- He retained about 91% of his direct holding immediately before the sale.
Table of Contents
- Medtronic insider sale followed a prearranged plan
- Remaining ownership puts the transaction in perspective
- Conclusion
Medtronic insider sale followed a prearranged plan
Marinaro’s SEC Form 4 transaction disclosure states that the sale was made under a Rule 10b5-1 plan adopted on March 17, 2026. That detail distinguishes the October execution date from the earlier decision to establish the trading arrangement.
The filing lists an execution price of $96, rather than merely a market quotation near the time of the sale. Multiplying that price by the 10,420 shares sold gives gross proceeds of $1,000,320, before any fees or taxes.
The disclosure was signed on October 16, one day after the transaction. It identifies Marinaro as the executive responsible for Medtronic’s Medical Surgical and Americas businesses.
| Item | Details |
|---|---|
| Stock ticker | MDT |
| Security | Ordinary shares |
| Ownership form | Direct |
| Transaction classification | Sale, reported with Form 4 transaction code S |
Remaining ownership puts the transaction in perspective
Adding the shares sold to the reported remaining balance gives a direct pre-sale holding of 116,336 shares. The transaction therefore reduced that position by approximately 9%, leaving Marinaro with roughly 91% of it.
The prearranged-plan disclosure provides useful context, but it does not establish Marinaro’s personal reason for selling. Neither the transaction nor the remaining holding, on its own, establishes his assessment of Medtronic’s business outlook.
This was a sale of an executive’s existing shares, not an issuance of new stock by Medtronic. The proceeds therefore belong to the seller rather than representing capital raised by the medical-device maker.
Conclusion
The disclosure documents a completed sale under an existing trading plan, with Marinaro retaining most of his direct holding. It provides no schedule for further sales; any subsequent ownership changes would require separate disclosure.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
